(Q40331569)

English

Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy

scientific article published on 8 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1 reference

based on heuristic

inferred from title

methylprednisolone

1 reference

based on heuristic

inferred from title

Dario Roccatello

1

object named as

Dario Roccatello

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Savino Sciascia

2

object named as

Savino Sciascia

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

3

object named as

Daniela Rossi

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Elisa Menegatti

7

object named as

Elisa Menegatti

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

author name string

Mirella Alpa

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Carla Naretto

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Simone Baldovino

6

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Rita La Grotta

8

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Vittorio Modena

9

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

language of work or name

0 references

publication date

8 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Nephrology Dialysis Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

3987-3992

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Rituximab and lupus: Good in real life, bad in controlled trials. comment on the article by Lu et al

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Six refractory lupus patients treated with rituximab: a case series

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

B cell-directed therapies for autoimmune disease and correlates of disease response and relapse

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Roles of B cells in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Regulatory roles for cytokine-producing B cells in infection and autoimmune disease

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Systematic review: agranulocytosis induced by nonchemotherapy drugs

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Rituximab-associated infections

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Rituximab as a therapeutic tool in severe mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Rituximab in cryoglobulinemic peripheral neuropathy.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Lupus nephritis: where are we now?

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFR109

21 January 2018

Identifiers

10.1093/NDT/GFR109

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40331569&oldid=1983240373"